Fmr LLC Has $411,000 Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Fmr LLC lifted its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 105.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 52,779 shares of the medical instruments supplier’s stock after acquiring an additional 27,031 shares during the quarter. Fmr LLC’s holdings in AngioDynamics were worth $411,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ANGO. Segall Bryant & Hamill LLC increased its stake in AngioDynamics by 142.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock valued at $7,091,000 after buying an additional 535,958 shares during the period. Millennium Management LLC grew its holdings in shares of AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after acquiring an additional 529,861 shares in the last quarter. First Eagle Investment Management LLC acquired a new position in shares of AngioDynamics in the second quarter worth $1,321,000. Systematic Financial Management LP increased its stake in shares of AngioDynamics by 8.4% in the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock worth $12,763,000 after acquiring an additional 162,972 shares during the last quarter. Finally, Royce & Associates LP raised its holdings in shares of AngioDynamics by 10.8% during the third quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier’s stock worth $7,672,000 after acquiring an additional 96,138 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ANGO. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research note on Tuesday, December 10th. Canaccord Genuity Group lowered their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th.

Insider Buying and Selling

In other news, CEO James C. Clemmer bought 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the acquisition, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at $4,109,939.46. The trade was a 3.02 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders purchased 22,568 shares of company stock worth $135,847. 5.40% of the stock is currently owned by insiders.

AngioDynamics Trading Down 3.9 %

ANGO stock opened at $8.58 on Friday. The firm has a market cap of $348.64 million, a PE ratio of -1.41 and a beta of 0.68. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $9.58. The company has a fifty day simple moving average of $7.26 and a 200 day simple moving average of $7.03.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business’s quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.12) earnings per share. As a group, analysts forecast that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.